Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center
Articles by Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center
Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.
Tumor Agnostic RET Inhibition: The ARROW Trial
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Dr Jyoti Patel presents data from the ARROW clinical trial.
Tumor Agnostic RET Inhibition: The LIBRETTO-001 Trial
ByMark A. Socinski, MD, Advent Health Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Lori Wirth, MD, reviews the phase 1/2 LIBRETTO-001 trial.
TRK Fusion Inhibitors in Clinical Practice
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Experts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.
TRK Fusion Inhibitors in Tumor-Agnostic Clinical Trials
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Jonathan Trent, MD, PhD, describes the safety and efficacy data from clinical trials of larotrectinib in patients with NRTK fusion–positive solid tumors.
Treatment Options for NRTK Fusion–Positive Solid Tumors
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Benjamin Levy, MD, reviews the available treatment options for patients whose tumors harbor NRTK fusions.
NRTK Fusions in Oncology
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Dr Lori Wirth describes the importance and implications of testing for NRTK fusions in patients with solid tumors.
Solid Tumors: Unmet Needs Related to Biomarker-Driven Therapy
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Dr Mark Socinski and panel discuss the challenges and unmet meets of biomarker-driven therapy across solid tumor types.
Companion Diagnostics in Oncology for Solid Tumors
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Experts in oncology provide their insights on the use of companion diagnostics in the treatment of solid tumors.
Pan-Tumor Biomarker Testing in Oncology
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center A panel of oncology experts in lung, thyroid, and sarcomatous tumors discuss the role and impact of pan-tumor biomarker testing.
Key Considerations for Biomarker Testing
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Jyoti Patel, MD, FASCO, discusses the pros and cons of tissue versus blood for molecular testing of solid tumors.
Importance of Biomarker Testing for Solid Tumors
ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center Benjamin Levy, MD, and a multispecialty panel of experts discuss the importance of biomarker-directed therapy for appropriate solid tumors.
Evolving Field of Molecular Testing in Non–Small Cell Lung Cancer
Importance of Biomarker Testing for Solid Tumors
Key Considerations for Biomarker Testing